Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ChatNSG: An Overview of Contemporary and Emerging Artificial Intelligence Models for the Neurosurgeon.

Journal of neurological surgery. Part B, Skull base·2026
Same author

Dual tumour-myeloid targeting of glioblastoma with GPNMB CAR-T cells.

Nature·2026
Same author

Murine modeling of IDH-mutant 1p/19q-codeleted oligodendroglioma reveals genotype specific phenotypes.

bioRxiv : the preprint server for biology·2026
Same author

Phase 1 evaluation of patients with newly diagnosed glioblastoma treated with radiation, nivolumab, and IDO1 enzyme inhibitor BMS-986205.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

IL6 Supports Development of an Immunosuppressive Microenvironment and Resistance to Therapy in Glioblastoma.

Cancer research·2026
Same author

Reevaluating routine imaging: clinical utility of postoperative CT after stereotactic brain biopsy.

Journal of neurosurgery·2026

Related Experiment Video

Updated: Apr 20, 2026

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis
09:21

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis

Published on: March 20, 2026

110

Therapeutic targets in subependymoma.

Ling-Yuan Kong1, Jun Wei1, Ali S Haider1

  • 1Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.

Journal of Neuroimmunology
|December 4, 2014
PubMed
Summary

Subependymomas lack defined medical therapies. This study identified molecular targets and tested inhibitors, finding WP744 and WP1066 effectively inhibited subependymoma cell growth.

Keywords:
EpendymomaImmunotherapyNoninvasiveSubependymoma

More Related Videos

Image-Guided Resection of Glioblastoma and Intracranial Implantation of Therapeutic Stem Cell-seeded Scaffolds
09:18

Image-Guided Resection of Glioblastoma and Intracranial Implantation of Therapeutic Stem Cell-seeded Scaffolds

Published on: July 16, 2018

8.9K
Modeling Astrocytoma Pathogenesis In Vitro and In Vivo Using Cortical Astrocytes or Neural Stem Cells from Conditional, Genetically Engineered Mice
10:13

Modeling Astrocytoma Pathogenesis In Vitro and In Vivo Using Cortical Astrocytes or Neural Stem Cells from Conditional, Genetically Engineered Mice

Published on: August 12, 2014

14.1K

Related Experiment Videos

Last Updated: Apr 20, 2026

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis
09:21

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis

Published on: March 20, 2026

110
Image-Guided Resection of Glioblastoma and Intracranial Implantation of Therapeutic Stem Cell-seeded Scaffolds
09:18

Image-Guided Resection of Glioblastoma and Intracranial Implantation of Therapeutic Stem Cell-seeded Scaffolds

Published on: July 16, 2018

8.9K
Modeling Astrocytoma Pathogenesis In Vitro and In Vivo Using Cortical Astrocytes or Neural Stem Cells from Conditional, Genetically Engineered Mice
10:13

Modeling Astrocytoma Pathogenesis In Vitro and In Vivo Using Cortical Astrocytes or Neural Stem Cells from Conditional, Genetically Engineered Mice

Published on: August 12, 2014

14.1K

Area of Science:

  • Neuro-oncology
  • Molecular Biology
  • Immunology

Background:

  • Subependymomas are rare tumors with limited non-surgical treatment options.
  • Lack of molecular and immunological characterization hinders development of alternative therapies.

Purpose of the Study:

  • To investigate the immune microenvironment and molecular pathways in subependymomas.
  • To identify potential therapeutic targets and test cytotoxic agents against subependymoma cells.

Main Methods:

  • Ex vivo analysis of the subependymoma immune microenvironment.
  • Cytokine/chemokine microarray and tissue microarray construction.
  • Derivation of a subependymoma cell line for drug sensitivity testing.

Main Results:

  • Subependymomas exhibit detectable immune effectors without significant immune suppression.
  • Tumor expression of p53, MDM2, HIF-1α, topoisomerase II-β, p-STAT3, and nucleolin was confirmed.
  • Topoisomerase and p-STAT3/HIF-1α inhibitors (WP744, WP1066) significantly inhibited subependymoma cell proliferation.

Conclusions:

  • Targeting identified oncogenic pathways with specific inhibitors shows promise for subependymoma treatment.
  • These findings provide a basis for developing novel medical therapies for non-surgical subependymoma candidates.